TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19897063
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 3, n=14)
Study: 7790794
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy
Study: 7790794
Drug: Amitriptyline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline therapy
Study: 371048
Drug: Kanamycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin (1 gm four times a day) and erythromycin (750 mg three times a day)
Study: 31772611
Drug: Inulin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (15 g for 21 days)
Study: 31772611
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 15 g for 21 days)
Study: 28592166
Drug: Continuous bilateral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bilateral thoracic paravertebral infusion of 0.5% lidocaine (1 mg.kg‐1.hr‐1)
Study: 28592166
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion of lidocaine at the same rate through catheters inserted at the same locations
Study: 24958605
Drug: CE‐then‐AT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE‐then‐AT + RT (8 weeks of 'sham' training followed by 8 weeks concurrent aerobic and resistance training)
Study: 21527575
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) doses of 30 mg, 50 mg, and 70 mg
Study: 15084807
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE) 20 mg/kg/day (max. 500 mg) b.i.d. for 5 days
Study: 15084807
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (PenV) 50,000 IU/kg (30 mg/kg) t.i.d. for 10 days
Study: 26068576
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Cisplatin with sequential gefitinib (arm B)
Study: 22190027
Drug: Exercise-induced dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise-induced dehydration with no diuretic (DN)
Study: 22190027
Drug: Exercise-induced dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise-induced dehydration plus diuretic (DD; furosemide, 40 mg)
Study: 20704666
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of steroid
Study: 20704666
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of local anesthetic
Study: 20704666
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of saline
Study: 20704666
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of steroid
Study: 15773400
Drug: Inactivated poliomyelitis
Normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliomyelitis vaccine (IPV) 'Imovax Polio'
Study: 15773400
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine (following IPV)
Study: 10417577
Drug: Botox injections
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injections to the glabella, forehead or lateral canthal regions
Study: 7732714
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/day (lipid-lowering drug)
Study: 2277377
Drug: Cefmetazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (1 g intramuscularly preoperatively)
Study: 2277377
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 g intramuscularly preoperatively)
Study: 17557045
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment for extraesophageal manifestations of GER
Study: 14994324
Drug: Lormetazepam oral
Normalized name: lormetazepam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam oral solution
Study: 14994324
Drug: Lormetazepam tablets
DrugBank: Lormetazepam (DB13872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam tablets
Study: 10197085
Drug: hGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH therapy (0.125U/kg/wk increasing to 0.25U/kg/wk)
Study: 10197085
Drug: hGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH therapy
Study: 4042528
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nicotine base in a 30% aqueous solution
Study: 4042528
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo solution
Study: 28965648
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone with supportive strategies
Study: 27052743
Drug: Autologous CIK
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CIK cell immunotherapy in combination with chemotherapy (FOLFOX4 plan)
Study: 27052743
Drug: Chemotherapy (FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FOLFOX4 plan) alone
Study: 25461784
Drug: Technician-administered internet
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technician-administered internet cognitive behaviour therapy (iCBT)
Study: 22956251
Drug: VBLOC® Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBLOC® Therapy (vagal blockade)
Study: 22956251
Drug: VBLOC® Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBLOC® Therapy (vagal blockade) with ≥ 12 h/day use
Study: 20202489
Drug: naproxcinod 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 375 mg
Study: 20202489
Drug: naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 750 mg
Study: 20202489
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg
Study: 17967821
Drug: Late CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late CPAP (CPAP added to medical treatment for 15 min)
Study: 8638755
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program with patellar taping
Study: 8638755
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program without patellar taping
Study: 4048835
Drug: Fat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat (50 g)
Study: 4048835
Drug: Protein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (50 g)
Study: 4048835
Drug: Starch (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch (50 g)
Study: 31204114
Drug: DMPA‐IM (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA‐IM (150 mg/mL every 3 months)
Study: 15194131
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg as a single shot
Study: 15194131
Drug: Gatifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 200 mg once daily for 3 days
Study: 8424511
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine in 25 mL of saline (Group 1)
Study: 8424511
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of 0.25% bupivacaine (62.5 mg) (Group 2)
Study: 8424511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5 mg of morphine and 62.5 mg of bupivacaine in 25 mL dilution (Group 3)
Study: 8424511
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL of saline (Group 4)
Study: 3318543
Drug: Morphine 33
Normalized name: morphine sulfate 33 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 33 micrograms/minute
Study: 29161166
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (motivational element, quitting preparation components, pre-quit nicotine patch)
Study: 27480840
Drug: Alogliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin with ACE inhibitor
Study: 27480840
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with ACE inhibitor
Study: 27480840
Drug: Alogliptin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin without ACE inhibitor
Study: 27480840
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without ACE inhibitor
Study: 27480840
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of ACE inhibitor
Study: 11912360
Drug: Vehicle saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle saline solution
Study: 9707351
Drug: (R)-propranolol 80
Normalized name: propranolol hydrochloride 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-propranolol 80 mg
Study: 9707351
Drug: (S)-propranolol 80
Normalized name: propranolol hydrochloride 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-propranolol 80 mg
Study: 9707351
Drug: rac-propranolol 160
Normalized name: propranolol hydrochloride 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rac-propranolol 160 mg
Study: 8520187
Drug: 200‐mg vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg vaginal progesterone suppositories
Study: 1669270
Drug: Immunotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy in A Group (10 patients)
Study: 31593588
Drug: CMV gB/MF59
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB/MF59 vaccine
Study: 28131322
Drug: Dalfampridine extended
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine extended release (D-ER) 10 mg BID
Study: 21333385
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin infusion without nasogastric tube placement (erythromycin group)
Study: 21333385
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin infusion combined with nasogastric tube placement (nasogastric-erythromycin group)
Study: 19892392
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (Oportunidades programme for 18 months earlier)
Study: 19892392
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment (Oportunidades programme started 18 months later)
Study: 16881772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication management and intensive behavior therapy (Comb)
Study: 16881772
Drug: Community-treated comparison
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-treated comparison (CC)
Study: 11339912
Drug: Polymorphism of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphism of interleukin‐1 receptor antagonist gene
Study: 11339912
Drug: Three mutant
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three mutant alleles of interleukin‐1 beta and interleukin‐1 receptor antagonist genes
Study: 9198829
Drug: Thyroxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxin treatment (started on average 5 years after surgery)
Study: 9198829
Drug: Thyroxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxin treatment (permanently treated)
Study: 9198829
Drug: Thyroxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxin treatment (in patients with nodular regrowth)
Study: 9198829
Drug: Thyroxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxin treatment (in patients with high serum TSH concentrations)
Study: 1586270
Drug: Haloperidol low
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol low dose (2 to 13 ng/mL)
Study: 1586270
Drug: Haloperidol medium
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol medium dose (13.1 to 24 ng/mL)
Study: 1586270
Drug: Haloperidol high
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol high dose (24.1 to 35 ng/mL)
Study: 3894872
Drug: Caffeine solution
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine solution (5 mg X kg‐1 body weight)
Study: 3894872
Drug: Electrolyte‐glucose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte‐glucose solution (ERG)
Study: 28423480
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (20,000 IU)
Study: 28423480
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D3 (800 IU)
Study: 21518220
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Study: 21518220
Drug: Atazanavir/ritonavir (ATZ/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Study: 18350281
Drug: 333 mg
Normalized name: aspirin 333 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 333 mg Salvia extract
Study: 18350281
Drug: 167 mg
Normalized name: silymarin 167 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 167 mg Salvia extract
Study: 18350281
Drug: 666 mg
Normalized name: lactulose 666 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 666 mg Salvia extract
Study: 18350281
Drug: 1332 mg
Normalized name: imdevimab 1332 MG in 11.1 MG Injection (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1332 mg Salvia extract
Study: 17068306
Drug: rt-PA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (intravenous recombinant tissue plasminogen activator)
Study: 14535908
Drug: Remifentanil (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (loading dose 1 microg x kg(‐1); maintenance infusion, 0.25 microg x kg(‐1) min(‐1))
Study: 14535908
Drug: Alfentanil (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (loading dose 50 microg x kg(‐1); maintenance infusion, 1 microg x kg(‐1) min(‐1))
Study: 8838433
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily (increased to 10 mg if necessary)
Study: 8838433
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg twice daily (increased to 180 mg if necessary)
Study: 3900155
Drug: Placebo (initially)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initially) then crossed over to 3% topical minoxidil
Study: 3793950
Drug: Conventional quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional quinidine sulfate 300 mg q6h
Study: 3793950
Drug: Sustained-release quinidine
Normalized name: quinidine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release quinidine sulfate 600 mg q12h
Study: 3793950
Drug: Sustained-release quinidine
Normalized name: quinidine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release quinidine gluconate 648 mg q12h
Study: 16817580
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities (sitting, walking, running, jumping jacks, vertical leap, jumping off a step)
Study: 14570661
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus administration of fentanyl (0.03 mg followed by 0.1 mg 210 min later)
Study: 14570661
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl (0.03 mg/h followed by 0.1 mg/hr 210 min later for 200 min)
Study: 14570661
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl
Study: 14570661
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus administration of fentanyl
Study: 10894961
Drug: Daily repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily repeated applications of moisturizers (twice daily for 5 days)
Study: 4004715
Drug: Weight-loss treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-loss treatment groups defined by homogeneity (similar gender and degree of overweight)
Study: 4004715
Drug: Weight-loss treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-loss treatment groups defined by heterogeneity (dissimilar gender and degree of overweight)
Study: 31699516
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics (AP); 92% of patients received this intervention; 74% received AP monotherapy; 79.5% received off-label AP prescriptions.
Study: 31699516
Drug: First 3
Normalized name: 3-Step First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 3 months of treatment; noted as a significant period for AEs.
Study: 20837824
Drug: Pioglitazone (Actos),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (Actos), 45 mg daily, plus 200 IU of vitamin E daily
Study: 20837824
Drug: Placebo, plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, plus 200 IU of vitamin E daily
Study: 18952945
Drug: Non-interruptive medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interruptive medication laboratory alerts
Study: 17196292
Drug: Spa Therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa Therapy (ST)
Study: 7807701
Drug: Flucytosine (5‐FC)
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flucytosine (5‐FC) in combination with fluconazole (FLCZ) at half doses
Study: 591625
Drug: Oral L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral L-tryptophan (90 mg/kg BW)
Study: 23677794
Drug: Brief 3-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief 3-minute drug advice (control; n=161)
Study: 15071125
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of torcetrapib daily
Study: 15071125
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of torcetrapib twice daily
Study: 9393430
Drug: Implant designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant designs with higher success rates
Study: 9393430
Drug: Specific implant
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific implant design
Study: 8200949
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) low dose (0.4 IU/kg.week)
Study: 8200949
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) high dose (1.2 IU/kg.week)
Study: 3147809
Drug: Nifedipine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10, 20, and 30 mg tid)
Study: 3147809
Drug: Propranolol (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20, 40, and 80 mg tid)
Study: 21905094
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin B complex
Study: 16554289
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg for 3 days followed by ER ciprofloxacin 1000 mg
Study: 16554289
Drug: ER ciprofloxacin
Normalized name: ciprofloxacin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER ciprofloxacin 1000 mg
Study: 14653226
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg quazepam administered 2 hours after a meal
Study: 8873541
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1.37 ng/ml
Study: 8873541
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 32 ng/ml
Study: 8873541
Drug: Isoflurane alone
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane alone (0 ng/ml remifentanil)
Study: 3132055
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg and midazolam 0.05 mg/kg
Study: 3132055
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg alone
Study: 21337043
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - two injections of 1.25 mg IVB 6 weeks apart
Study: 12612157
Drug: TOP/beta-glucan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP/beta-glucan treatment (1.8 g TOP and 2.8 g beta-glucan/d)